Serenium, Inc. v. Zhou

CourtDistrict Court, N.D. California
DecidedJuly 22, 2021
Docket5:20-cv-02132
StatusUnknown

This text of Serenium, Inc. v. Zhou (Serenium, Inc. v. Zhou) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Serenium, Inc. v. Zhou, (N.D. Cal. 2021).

Opinion

1 2 3 UNITED STATES DISTRICT COURT 4 NORTHERN DISTRICT OF CALIFORNIA 5 SAN JOSE DIVISION 6 7 SERENIUM, INC., Case No. 20-cv-02132-BLF

8 Plaintiff, ORDER GRANTING DEFENDANTS’ 9 v. MOTION TO DISMISS THE SECOND AMENDED COMPLAINT 10 JASON ZHOU, et al., [Re: ECF 86] 11 Defendants.

12 13 Before the Court is Defendants’ Motion to Dismiss the Second Amended Complaint under 14 Fed. R. Civ. P 12(b)(2), (6), and (7) or to Compel Arbitration. Mot., ECF 86; see also Opp., ECF 15 93; Reply, ECF 100. The Court held a hearing on this motion on May 6, 2021. For the reasons 16 discussed at the hearing and below, the Court GRANTS the Defendants’ Motion to Dismiss for 17 Lack of Personal Jurisdiction WITHOUT LEAVE TO AMEND. 18 I. BACKGROUND 19 Serenium, a start-up company with its operational headquarters in Palo Alto, California 20 and a technology development office in San Diego, California, was founded to develop technology 21 relating to diagnosis and treatment of sleep apnea. ECF 82, Second Amended Complaint (“SAC”) 22 ¶ 1, 8. Serenium claims that it was approached by Defendant Jason Zhou (“Zhou”), a billionaire 23 with interests in the British Virgin Islands, Cayman Islands, Hong Kong, and China. SAC ¶¶ 13, 24 63. Zhou is the founder, CEO, chairman, and controlling shareholder of Defendant New Century 25 Healthcare Holding Co. Limited (“New Century”), which operates a number of hospitals in China. 26 SAC ¶ 13. The parties entered into a joint venture in which Serenium developed sleep apnea 27 technology and products that New Century would distribute and sell in Japan, South Korea, China, 1 Serenium disclosed its proprietary technology pursuant to a non-disclosure agreement (“NDA”) to 2 New Century. SAC ¶¶ 14-16, 20, 63-85. The NDA provided that it was “governed by Illinois 3 law.” SAC ¶ 76. 4 In late 2017, the parties began drafting Term Sheets that delineated the basic structure of 5 the joint venture. SAC ¶¶ 93, 94, 99. The Term Sheets expressly stated that they would be 6 replaced by a joint venture contract, known as the “Framework Contract,” which would in turn be 7 replaced by a detailed Shareholder Agreement. SAC ¶ 103. Beginning in January 2018, the parties 8 exchanged twenty-one Framework Contract drafts. SAC ¶ 104. The Framework Contract drafts 9 contemplated Serenium and Beijing Jiarun Yunzhong Health Technology Company Ltd. (“Beijing 10 Jiarun”) as parties. SAC ¶ 105. According to Serenium, Zhou and Defendant Jia Xiaofeng (“Jia”), 11 New Century’s Corporate Secretary and Beijing Jiarun’s CEO, falsely held out Beijing Jiarun as 12 part of New Century. SAC ¶¶ 17, 20, 105-108. Serenium and Beijing Jiarun ultimately opted not 13 to enter into the contract. SAC ¶¶ 111-112. 14 Zhou later proposed that Serenium and non-party New Century (International) Co. Limited 15 (“New Century International”), a New Century subsidiary, form a jointly owned holding company 16 in Hong Kong aimed at “bring[ing] Serenium’s technology to China and other Asian countries.” 17 SAC ¶¶ 113, 122. The holding company would allegedly be funded by New Century International, 18 while Serenium would contribute the technology. SAC ¶¶ 114-115. This agreement was 19 memorialized as the Framework Contract. See SAC ¶¶ 114-119. As part of the Framework 20 Contract, New Century International had the option to purchase 19.9% of Serenium’s equity based 21 on a $25 million valuation. SAC ¶ 115. 22 Given “the protracted but fruitful negotiation of the Framework Contract, Serenium hired 23 engineers and opened a San Diego Technology office.” SAC ¶ 120. As months passed, however, 24 New Century International failed to form the holding company contemplated by the Framework 25 Contract. SAC ¶ 121. In the meantime, Serenium began to attempt compliance with Chinse 26 regulatory requirements. SAC ¶¶ 121-124. In August 2018, New Century, at Zhou’s direction, 27 resolved not to form the holding company, and instead represented to Serenium that it needed 1 Serenium to provide yet more information about its trade secrets so that New Century and Beijing 2 Jiarun could use this information in providing their own in-house adult and pediatric sleep 3 diagnostics and treatment. For this reason, New Century, Zhou, and Jia withheld from Serenium 4 Zhou and New Century’s decision to abandon the JV.” SAC ¶ 130. Serenium continued to share 5 its proprietary information, business plans, testing equipment, and trade secrets. SAC ¶¶ 131-135. 6 For example, in October 2018, Serenium trained hundreds of doctors and medical professionals— 7 represented to be employees of New Century—in Beijing on Serenium’s technology. SAC ¶ 135. 8 By late 2018, the relationship between the parties broke down as Zhou refused to form the 9 holding company. SAC ¶ 137. In March 2019, New Century International terminated the 10 Framework Contract. New Century, however, refused to return Serenium’s proprietary oximeters 11 and failed to return or destroy Serenium’s trade secrets as required by the NDA. SAC ¶¶ 140-141. 12 According to Serenium, New Century is currently diagnosing and treating patients with 13 Serenium’s confidential information and intellectual property. SAC ¶ 142. 14 On March 27, 2020, Serenium sued New Century for breach of contract, see SAC ¶¶ 211- 15 223, and New Century, Zhou, and Jia for misappropriation of trade secrets under 18 U.S.C. §§ 16 1836(b) and 1837, see SAC ¶¶ 224-250 and California Civil Code §§ 3426, et seq., see SAC ¶¶ 17 251-254. Serenium’s claims are predicated solely on New Century’s obligations flowing from and 18 conduct related to the NDA. SAC ¶¶ 212, 226, 242. Accordingly, the Court is precluded from 19 considering factual allegations related to the Framework Contract, to which nonparty New 20 Century International was a signatory. 21 II. DISCUSSION 22 At top, the Court recognizes that Plaintiff has made extensive amendments to the 23 pleadings. Compare SAC with First Amended Complaint (“FAC”), ECF 14. These amendments 24 provide valuable details about the relationship between the parties and the relationship between 25 Defendants and the State of California. See, e.g., SAC ¶¶ 164-210. Nonetheless, the new 26 allegations do not shift the fundamental nature of Defendants’ connection to the State of 27 California, and Plaintiff cannot escape this Court’s previous conclusion that it lacks jurisdiction 1 PREJUDICE. 2 A. Lack of Personal Jurisdiction, Fed. R. Civ. P. 12(b)(2) 3 When a defendant raises a challenge to personal jurisdiction, the plaintiff bears the burden 4 of establishing that jurisdiction over each defendant is proper. Ranza v. Nike, Inc., 793 F.3d 1059, 5 1068 (9th Cir. 2015). “Although the plaintiff cannot ‘simply rest on the bare allegations of its 6 complaint,’ uncontroverted allegations in the complaint must be taken as true. Conflicts between 7 parties over statements contained in affidavits must be resolved in the plaintiff's favor.” 8 Schwarzenegger v. Fred Martin Motor Co., 374 F.3d 797, 800 (9th Cir. 2004) (internal citations 9 omitted). For a court to exercise personal jurisdiction over a nonresident defendant, that defendant 10 must have at least “minimum contacts” with the relevant forum such that the exercise of 11 jurisdiction “does not offend traditional notions of fair play and substantial justice.” Id. at 801 (9th 12 Cir. 2004) (quoting International Shoe Co. v. Washington, 326 U.S. 310, 316 (1945)).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
McGee v. International Life Insurance
355 U.S. 220 (Supreme Court, 1957)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Helicopteros Nacionales De Colombia, S. A. v. Hall
466 U.S. 408 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Boschetto v. Hansing
539 F.3d 1011 (Ninth Circuit, 2008)
Walden v. Fiore
134 S. Ct. 1115 (Supreme Court, 2014)
Flood v. Bank of America Corporation
780 F.3d 1 (First Circuit, 2015)
Bernard Picot v. Dean Weston
780 F.3d 1206 (Ninth Circuit, 2015)
Loredana Ranza v. Nike, Inc.
793 F.3d 1059 (Ninth Circuit, 2015)
Axiom Foods, Inc. v. Acerchem International, Inc.
874 F.3d 1064 (Ninth Circuit, 2017)
Dole Food Co. v. Watts
303 F.3d 1104 (Ninth Circuit, 2002)
Schwarzenegger v. Fred Martin Motor Co.
374 F.3d 797 (Ninth Circuit, 2004)
Roth v. Garcia Marquez
942 F.2d 617 (Ninth Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Serenium, Inc. v. Zhou, Counsel Stack Legal Research, https://law.counselstack.com/opinion/serenium-inc-v-zhou-cand-2021.